Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Exclusion Criteria

• •A history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years.
• •A history of allogeneic stem-cell transplantation
• •Primary central nervous system (CNS) tumors including primary CNS lymphoma
• •Central nervous system involvement by lymphoma
• •Myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (New York Heart Association \>class II), unstable angina, or unstable cardiac arrhythmia requiring medication
• •Vorinostat cohorts only: History of significant GI surgery or disease, which would impair intestinal absorption
• •Vorinostat cohorts only: Active peptic ulcer disease
• •Prior exposure to AMG 655 or other investigational TRAIL receptor agonists is not permitted
• •Prior treatment with bortezomib or vorinostat is not permitted for subjects enrolling in the bortezomib and vorinostat cohorts, respectively
• •Major surgery within 28 days before the first dose of AMG 655